Download Sample
Schedule a Meeting
Table of Content
NA : +1 804 441 9344
sales@towardspackaging.com
October 2025
The Europe glass prefilled syringes and glass vials packaging equipment market is projected to reach USD 389.13 million by 2034, growing from USD 238.3 million in 2025, at a CAGR of 5.6% during the forecast period from 2025 to 2034. Technological advancements in automation, robotics, and integrated packaging solutions drive improved throughput, precision, and reduced contamination risk, making the equipment vital for high-quality pharmaceutical manufacturing across Europe. The scope also includes software integration for monitoring, quality control, and real-time process optimization.
.webp "Europe Glass Prefilled Syringes And Glass Vials Packaging Equipment Market Size 2024 - 2034")
Europe glass prefilled syringes and glass vials packaging equipment market covers specialized machinery and systems for filling, capping, labelling, inspecting, and handling glass prefilled syringes and vials. This includes equipment for washing, sterilizing, filling, sealing, and automated inspection of pharmaceutical containers, ensuring compliance with regulatory requirements, sterile handling, and operational efficiency. The market addresses pharmaceutical manufacturers, biotechnology companies, CMOs, and research organizations, supporting injectable drug production, vaccines, biologics, insulin, and other therapeutics.
| Metric | Details |
| Market Size in 2024 | USD 225.66 Million |
| Projected Market Size in 2034 | USD 389.13 Million |
| CAGR (2025 - 2034) | 5.6% |
| Market Segmentation | By Equipment Type, By End-Use Industry,By Application and By Packaging Type |
| Top Key Players | Becton Dickinson (BD), SGD Pharma, Ompi (Stevanato Group), Ypsomed, Bormioli Pharma, Vetter Pharma, Roche, etc. |
The current PFS design now frequently includes safety mechanisms that automatically revoke the needle or cover it after every usage. These inventions lower the risk of needlestick injuries, which remain a serious occupational hazard for healthcare workers. These syringes enable the storage of lyophilized drugs and diluents independently, which are only integrated at the time of management.
This is specifically advantageous for the biologics and vaccines that have constant things in liquid form. Development in digital health has led to the growth of auto-injectors, which include smart features like injection reminders, dose tracking, and Bluetooth Connectivity with health apps. This tech-developed strategy assists perfect medication adherence, particularly for chronic disease management.
Regular glass syringes are now being substituted or supplemented with cyclic olefin polymer (COP) and Cyclic olefin copolymer alternatives. These materials have developed better compatibility, break resistance, and have fragile biologics that lower down communication with drug formulations and lower the risk of particulate contamination.
The world imported 129 shipments of Glass syringes from India during the period October 2023 to September 2024. These imports were being supplied by 26 Indian exporters to 46 World buyers, which marks a growth rate of -10% as compared to the previous twelve months.
Within this time, in September 2024 alone, the World has imported 8 Glass Syringe shipments. This marks a year-on-year development of 33% as compared to September 2023, and a 0% series increase from August 2024.
The world has officially imported most of the Glass Syringes from the United States, Mexico, and India.
Globally, the top three importers of the Glass Syringe are Mexico, the United States, and China. The United States tops the world in Glass Syringe imports, having 8,389 shipments, followed by Mexico with 1,452 shipments, and China taking the third position with 694 shipments.
The cleaning machines segment has dominated the market with a 38% share in 2024, as machines that clean prefilled syringes for packaging are specifically mixed into a bigger, automated pharmaceutical line. The latest manufacturing lines for the pre-filled syringes often do not need cleaning equipment, as they use sterilised, nested syringes which are ready for fast filling.
Hence, for lines that use the glass syringes that are not pre-sterilized, washing and cleaning are important steps. These cleaning machines utilise steps. These cleaning equipment utilise techniques such as ultrasonic baths and pressurized washing to ensure sterility before filling.
The filling machine segment is expected to be the fastest in the market with a 26% CAGR during the forecast period. Many pharmaceutical sector machine produces filling machines for the glass pre-filled syringes. These highly technical machines run in aseptic conditions and frequently need several stages, such as vacuum filling, automatic syringe loading, and stoppering. Several PFS Filling machines are constructed with stainless steel elements for spaces that contact with product and crafted to run within isolated, cleanroom surroundings to prevent pollution. Automated systems are utilised to process ‘nested’ syringes which come in trays. The machine can automatically remove the protective liner and carry the syringes without human contact to track sterility.
Several systems are crafted as a complete production line that can include ensuing procedures like labelling and plunger rod insertion.
The pharmaceutical manufacturers segment has dominated the market with a 45% share in 2024 as they use glass vials for bulk storage of injectable and other drug products, while prefilled glass syringes are filled with a single, pre-measured dose for direct administration. Both are produced from chemically inert, constant borosilicate glass to protect against drug degradation and pollution, too.
During the production procedure, vials are being sterilised through washing and dehydrogenation before entering an aseptic filling suite. They are then filled with the drug product and packed with a rubber stopper having a crimped aluminum cap. Type 1 borosilicate glass is chemically filled and highly resistant to temperature updates, which makes it perfect for keeping sensitive biotech drugs and vaccines that need cold-chain storage.
The contract packaging segment is expected to be the fastest in the market with a 28% share during the forecast period. Packaging plays a crucial role in glass syringes and glass vials by delivering several functions such as promotion, presentation, information dissemination, compliance, and identification of a drug product. It also ensures protection during storage, distribution, sale, and consumption. One main factor that drives the industry is the growing urge for complicated packaging products, customised and specifically biologics, personalized medicines. These items make the compulsion of tailored packaging due to their different characteristics. Contract packaging suppliers have given feedback by developing their technical expertise and resources to meet these intricate packaging needs and demands.
The vaccines segment has dominated the market with a 50% share in 2024 as prefilled syringes are sterile packaging that carries pre-measured doses of drugs, which are ready for immediate usage. It is crafted to save time and nursing costs by enabling pre-loading medication into syringes. This also assists in making sure accuracy when halting, making time by 50%. They are perfect for dermal fillers, vaccines, or fragile biopharmaceuticals -ensuring safety, consistency, and the fastest workflows. The Prefillable syringes are updating drug delivery for the business globally.
The monoclonal antibodies segment is predicted to be the fastest in the market with a 22% share during the forecast period. Monoclonal antibodies are the same molecules that are derived from a single B Cell, which are crafted to recognise a single specific antigen. Just like polyclonal antibodies, which communicate with several epitopes on the same antigen, monoclonal antibodies bind to just one defined epitope. This focused strategy develops the consistency and reliability of outcomes across various experimental uses such as western blotting, immunohistochemistry, enzyme immunoassays, and immunoprecipitation.
The prefilled syringes segment dominated the market share of 55% in 2024 as prefilled design specifically includes a syringe needle, needle cover, plunger, and sometimes developed with a lure lock or other lined devices for secure drug delivery system attachment. They may be created from glass syringes or polymer materials; each is selected to update human factors, shelf life, and reliability with the biological items. For instance, prefilled syringes need less handling than regular syringe and vial systems, which smooths the fulfilment procedure and reduces the risk of medication errors.
The glass vials segment are predicted to be the fastest growing in the market with a 20% share during the forecast period. Tubular pharmaceutical vials for the injectable medicines are specifically made from the Type 1 borosilicate glass, which can come in several tubing designs. 51 stretched borosilicate glass tubing is the most prevalent, although 33 expansion borosilicate is a long-term =term storage solution for healthcare with different capabilities in order to maintain the pharmaceutical making.
In Europe, glass prefilled syringes are a dominant but transforming industry, which is being driven by the development of injectable biologics but experiencing competition from high-level plastic alternatives. On the other hand, glass is still chosen for its perfect barrier characteristics, plastic serves greater reliability and is catching a greater share of the market for uses. The factors that drive the growth of injectable biosimilars and biologics in Europe are a major driver.
The German region has dominated the market with a 32% share in 2024, as the trend for glass prefilled syringes in the German region is one of rapid development and continued dominance over plastic alternatives, which is being driven by the growing demand for an aging population and biologics. While plastic syringes are also developed, glass remains a selected choice material for high-value drug formulation due to its superior chemical inertness and stability. Struct European Union regulations, including the Needlestick-Injury Directive, are pushing the acceptance of prefilled syringes with mixed safety features.
Additionally, the trend towards home-based and outpatient diagnosis drives the growth of safe and user-friendly devices that allow for patient administration. The urge for highly fragile biologic drugs that need a constant and inert container is an initial driver for glass syringes. Biologics are predicted to account for over 30% of pharmaceutical sales by the year 2030.
The Switzerland region is predicted to be the fastest in the market with a 22% share during the forecast period. In Switzerland, as in the huge European market, the demand for glass prefilled syringes is classified by continued dominance, but with the rising uptake of high-level polymer alterations. The market is being driven by the high healthcare standards, a high-level pharmaceutical sector, and a concentration on administration for chronic diseases.
Switzerland’s high-level healthcare infrastructure and high standards for drug safety and invention market the usage of advanced drug delivery systems like PFS. Switzerland tends to meet with EU regulations for integrated and medical devices.
Tier 1
Tier 2
Tier 3
By Equipment Type
By End-Use Industry
By Application
By Packaging Type
October 2025
October 2025
September 2025
August 2025
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published40+
Consulting Projects Per Year25+
Analysts